C1q、SAA和IL-6水平在类风湿性关节炎患者不同时期的变化及意义
|
摘要
类风湿性关节炎(rheumatoid arthritis,RA)是临床上常见的疑难病症,是一种慢性、进行性的自身免疫性疾病(autoimmune disease, AID)。该病病因至今不明,可能与遗传、内分泌、地理、职业、营养、细菌和病毒感染以及心理和社会环境的差异等因素有关系,以慢性对称性的多滑膜关节炎和关节外病变为其主要临床表现。临床上该病好发于手、腕、足等一些小关节,反复发作,呈对称性分布,疾病早期表现为关节肿痛,继而软骨破坏、关节间隙变窄,晚期因严重的骨质破坏、吸收而导致关节出现僵直、畸形、功能障碍。该病预后不良,致残率较高。
临床上RA活动情况和病变程度的判断对该病的诊疗及预后均有很大意义,’一直以来,关于RA病情严重程度和早期诊断的评价指标都是研究的热点问题。目前临床上评价RA病情活动度需要综合诸多因素来判断,如肿胀关节数、疼痛及压痛关节数、晨僵时间、C-反应蛋白(C-reaction protein, CRP)、血沉(erythrocyte sedimentation rate, ESR)等,目前应用最广泛的评价标准是其中的DAS评分系统。近年来,随着仪器和检验技术的不断进步,临床上越来越重视对炎症指标的测定,希望找到更加敏感和特异的炎症指标,以便更好的为临床服务。
Clq作为补体经典激活途径的启动子,在防止组织免疫性损伤和清除体内循环免疫复合物等方面发挥着重要作用。目前,关于Clq的研究主要集中在系统性红斑狼疮(systemic lupus_erythematosus, SLE)患者中,而在RA患者中的研究比较少见,血清淀粉样蛋白A(serum amyloid A protein, SAA)是一种急性时相反应蛋白,属于载脂蛋白家族中的异质类蛋白质,相对分子量约12000。在急性时相反应中,SAA含量急剧升高,研究发现,在患炎性关节炎的案例中,血清淀粉样蛋白A与疾病活动性的关系最为密切。相关研究表明,SAA水平在RA患者血清中亦升高,并且更能反映RA的活动度。但SAA在RA发病机制中的作用目前尚不明确,需要继续探讨。RA是由免疫介导的慢性炎性疾病,其炎症和组织损伤涉及多种炎症因子,各种异常表达的炎症因子在RA的病程进展中均起着重要作用。研究发现,IL-6(lnterleukin-6)主要是由活化的单核细胞产生,是RA滑膜炎症和关节损伤的重要介质之一。相关研究表明, RA患者活动期血清中IL-6水平升高,并与病情活动的某些指标相关。因此本研究拟对不同时期的RA患者血清中C1q、SAA及IL-6的水平进行检测并与正常对照组进行比较,以探讨三者水平变化在RA不同时期患者中的临床诊断意义。
材料和方法
1.临床资料和方法
收集符合美国风湿病学会(ARA)1987年修订的分类标准的RA患者活动期和缓解期各50例及30例健康体检者的血液标本,离心后置于—80℃冰箱中保存备用,以备测定各组血清C1q、SAA及IL-6的水平。采用德国罗氏公司生产的罗氏P-800全自动生化分析仪,上海北加生化试剂有限公司生产的C1q试剂,以免疫透射比浊法(immunoturbidimetricassay, ITA)测定血清C1q。采用德国罗氏公司生产的罗氏cobas8000全自动生化分析和IL-6试剂,以电发学发光(electro chemiluminescence, ECL)法测定血清IL-6。采用上海赛默飞世尔仪器有限公司生产的Multiskan Mk3型酶标仪和美国R&D公司生产的SAA试剂盒,以酶联免疫吸附测定(enzyme-linkedimmunosorbent assay, ELISA)法测定血清SAA含量。以上所有操作均按试剂盒说明书严格操作。
2.统计学处理
采用SPSS17.0统计软件进行统计学分析,计量资料以均数±标准差(x±s)表示,组间比较采用单因素方差分析,以P<0.05为差异具有统计学意义。
结果
1.RA活动组患者50例,男性12例,女性38例,平均年龄(46.54±13.16)岁。RA缓解组患者50例,男性10例,女性40例；平均年龄(41.82±14.34)岁。正常对照组30例,男性10例,女性20例；平均年龄(43.03±13.35)岁。RA活动组、RA缓解组及正常对照组三组之间在年龄及性别构成等方面均无统计学差异(P均>0.05)。
2.RA活动组患者血清Clq、SAA和IL-6的水平分别为(27.32±8.31)mg/dl、(2953.91±874.17) μg/ml、(78.06±36.22) pg/ml, RA缓解组患者血清C1q, SAA和IL-6的水平分别为(22.41±4.91)mg/dl、(211.91±52.56)μg/ml、(5.47±1.65) pg/ml,正常对照组血清C1q, SAA和IL-6的水平分别为(16.62±4.86) mg/dl、(185.08±61.38)μg/ml、(2.38±0.47) pg/ml,RA患者活动组Clq水平高于缓解组和正常对照组,缓解组Clq水平高于正常对照组,差异具有统计学意义(P<0.05),RA患者活动组SAA和IL-6水平高于缓解组和正常对照组,差异具有统计学意义(P<0.05),RA患者缓解组SAA和IL-6水平与正常对照组相比无统计学意义(P>0.05)。
结论
1.RA活动期患者血清C1q、SAA及IL-6的水平均有高表达,RA患者体内C1q、SAA及IL-6水平的变化与RA疾病的活动度有关,它们可能成为RA病情监测和疗效判断的临床指标。
2. C1q、SAA及IL-6在RA的发生、发展过程中起着重要作用,探讨三者在RA发病机制中的作用,有利于观察RA的治疗效果,从而更好地指导RA的临床治疗。
Rheumatoid arthritis(RA) is a common difficult and baffling diseases in clinic, it is a chronic and progressive autoimmune disease(AID). Its etiology is unknown so far,and may be associated with heredity, endocrine, geography, occupation, nutrition, bacteria and virus infection,and psychological and social environment difference factors.The main clinical manifestations of RA include chronic, symmetry and many synovial arthritis and the extra-articular changes. Clinically, the disease occurs in the hand, wrist, feet and other small joints,it attacks recurrently and shows symmetric distribution.In the early stage，joint manifests swelling and pain,then articular cartilage is damaged and joint space narrows down,in the late stage, serious bone destruction and absorption lead to joint rigidity, deformity, dysfunction.The disease shows poor prognosis and has a high probability of disability.
Clinically,the judgment of pathological changes degree and activities of RA has great significance for the diagnosis and treatment and prognosis.All the time, the evaluation indictor,which evaluates early diagnosis and disease severity of RA,is the research hotspot problem.At present,the disease activity evaluation of RA needs to comprehensive judgment by many factors in clinic,such as the number of joint swelling,pain and tenderness joint number,morning stiffness time, C-reaction protein (CRP), erythrocyte sedimentation rate(ESR) and so on,disease activity score(DAS) rating system is currently the most widely used evaluation standard among the evaluation standards. In recent years, with the continuous improvement of instrument and inspection technique, the measurement of inflammation marker is also more and more be taken seriously,Clinicians hope to find more sensitive and specific inflammation marker, in order to provide better service for clinic.
Clq as the promoter of complement classic activation pathway, it plays an important role in preventing tissue autoimmune injury and clearing circulating immune complexes in vivo.At present, the research about Clq is mainly concentrated in patients with systemic lupus erythematosus,but in patients with RA is rarely founded. Serum amyloid A protein(SAA) is an acute phase protein, belongs to heterogeneous class protein of the apolipoprotein family, its relative molecular weight is about12000. In the acute phase reaction, SAA content increased sharply, the research found that serum amyloid A protein is most closely related to disease activity in the case of suffering from inflammatory arthritis. Related studies have shown that elevated serum SAA levels in patients with RA, and better reflect the activity of RA. However, the role of SAA in the pathogenesis of RA is not clear, so it needs to continue to discuss. RA is a chronic immune-mediated inflammatory diseases, its inflammation and tissue injury involves a variety of inflammatory cytokines, abnormal expression of various inflammatory factors play an important role in the progression of RA. The study found that lnterleukin-6(IL-6) is mainly produced by activated monocytes. It is one of the important mediators of synovial inflammation and joint injury of RA. Related studies have shown that IL-6levels increase in serum of patients with with RA in active stage, and is related to some indicators of disease activity. Therefore, this study intends to detect C1q,SAA and IL-6levels of different periods in the serum of patients with RA, and compares their levels with that of the normal control group,in order to investigate clinical significance of changes of the three levels of different periods in patients with RA.
Materials and Methods
1. Clinical data and methods
We collect50blood specimens of patients with RA in active stage and inactive stage respectively, all the RA patients fulfilled the American College of Rheumatology (ARA) revised criteria for classification in1987, and we also collect30healthy human blood specimens, then store them at-80℃refrigerator after centrifugation, our purpose is to detect Clq, SAA and IL-6levels in serum of the three groups.We use Roche P-800automatic biochemical analyzer produced by Germany Roche and Clq reagent produced by Shanghai Beijia biochemical reagent Co, Ltd to detect serum C1q levels by immunoturbidimetric assay(ITA).We use Roche cobas8000automatic biochemical analyzer and IL-6reagent produced by Germany Roche to detect serum IL-6levels by electro chemiluminescence(ECL) method. We use Multiskan Mk3type microplate reader produced by Shanghai Thermo Fisher Scientific Insrument Co, Ltd and SAA kit produced by the United States R&D company to detect serum SAA levels by enzyme-linked immunosorbent assay(ELISA) method. All operations are strictly operated according to the kit instructions.
2. Statistical analysis
The SPSS17.0statistical software package was used for statistical analysis.The measurement data were expressed by mean±standard deviation(x±s),the groups were compared by one-way ANOVA analysis, P value<0.05was considered significant.
Results
1In the group of50patients with RA in active stage,12subjects were male,38subjects were female,the mean age was (46.54±13.16) years old. In the group of50patients with RA in inactive stage,10subjects were male,40subjects were female, the mean age was (41.82±14.34) years old. In the group of30normal controls,10subjects were male,20subjects were female, the mean age was (43.03±13.35) years old. There were no statistical differences among the three groups in age and gender (P>0.05).
2The serum levels of C1q,SAA and IL-6in the group of patients with RA in active stage were (27.32±8.31) mg/dl、(2953.91±874.17) μg/ml、(78.06±36.22) pg/ml, the serum levels of C1q,SAA and IL-6in the group of patients with RA in inactive stage were (22.41±4.91) mg/dl、(211.91±52.56)μg/dl、(5.47±1.65) pg/ml, the serum levels of C1q,SAA and IL-6in the group of normal controls were (16.62±4.86) mg/dl、(185.08±61.38)μg/ml、(2.38±0.47) pg/ml. The serum Clq levels in the group of patients with RA in active stage was higher than that in the group of patients with RA in inactive stage and the normal control group, the serum Clq levels in the group of patients with RA in inactive stage was higher than that in the normal control group, and it has the statistical Signifcance (P<0.05), the serum SAA and IL-6levels in the group of patients with RA in active stage were higher than those in the group of patients with RA in inactive stage and the normal control group, and it has the statistical Signifcance (P<0.05), there were no statistical differences between the group of patients with RA in inactive stage and the normal control group in the serum SAA and IL-6levels(P>0.05).
Conclusions
1The serum levels of Clq, SAA and IL-6are highly expressed in the serum of patients with RA in active stage. The changes of serum C1q、SAA and IL-6levels in patients with RA have relations with the disease activity of RA, and they may become the clinical indicators of condition monitoring and curative effect assessment of patients with RA.
2Clq, SAA and IL-6play an important role in the occurrence and development process of RA.Discussing the role of the three in the pathogenesis of RA may be beneficial for observing the therapeutic effect of RA,so as to better guide the clinical treatment opf RA
临床上RA活动情况和病变程度的判断对该病的诊疗及预后均有很大意义,’一直以来,关于RA病情严重程度和早期诊断的评价指标都是研究的热点问题。目前临床上评价RA病情活动度需要综合诸多因素来判断,如肿胀关节数、疼痛及压痛关节数、晨僵时间、C-反应蛋白(C-reaction protein, CRP)、血沉(erythrocyte sedimentation rate, ESR)等,目前应用最广泛的评价标准是其中的DAS评分系统。近年来,随着仪器和检验技术的不断进步,临床上越来越重视对炎症指标的测定,希望找到更加敏感和特异的炎症指标,以便更好的为临床服务。
Clq作为补体经典激活途径的启动子,在防止组织免疫性损伤和清除体内循环免疫复合物等方面发挥着重要作用。目前,关于Clq的研究主要集中在系统性红斑狼疮(systemic lupus_erythematosus, SLE)患者中,而在RA患者中的研究比较少见,血清淀粉样蛋白A(serum amyloid A protein, SAA)是一种急性时相反应蛋白,属于载脂蛋白家族中的异质类蛋白质,相对分子量约12000。在急性时相反应中,SAA含量急剧升高,研究发现,在患炎性关节炎的案例中,血清淀粉样蛋白A与疾病活动性的关系最为密切。相关研究表明,SAA水平在RA患者血清中亦升高,并且更能反映RA的活动度。但SAA在RA发病机制中的作用目前尚不明确,需要继续探讨。RA是由免疫介导的慢性炎性疾病,其炎症和组织损伤涉及多种炎症因子,各种异常表达的炎症因子在RA的病程进展中均起着重要作用。研究发现,IL-6(lnterleukin-6)主要是由活化的单核细胞产生,是RA滑膜炎症和关节损伤的重要介质之一。相关研究表明, RA患者活动期血清中IL-6水平升高,并与病情活动的某些指标相关。因此本研究拟对不同时期的RA患者血清中C1q、SAA及IL-6的水平进行检测并与正常对照组进行比较,以探讨三者水平变化在RA不同时期患者中的临床诊断意义。
材料和方法
1.临床资料和方法
收集符合美国风湿病学会(ARA)1987年修订的分类标准的RA患者活动期和缓解期各50例及30例健康体检者的血液标本,离心后置于—80℃冰箱中保存备用,以备测定各组血清C1q、SAA及IL-6的水平。采用德国罗氏公司生产的罗氏P-800全自动生化分析仪,上海北加生化试剂有限公司生产的C1q试剂,以免疫透射比浊法(immunoturbidimetricassay, ITA)测定血清C1q。采用德国罗氏公司生产的罗氏cobas8000全自动生化分析和IL-6试剂,以电发学发光(electro chemiluminescence, ECL)法测定血清IL-6。采用上海赛默飞世尔仪器有限公司生产的Multiskan Mk3型酶标仪和美国R&D公司生产的SAA试剂盒,以酶联免疫吸附测定(enzyme-linkedimmunosorbent assay, ELISA)法测定血清SAA含量。以上所有操作均按试剂盒说明书严格操作。
2.统计学处理
采用SPSS17.0统计软件进行统计学分析,计量资料以均数±标准差(x±s)表示,组间比较采用单因素方差分析,以P<0.05为差异具有统计学意义。
结果
1.RA活动组患者50例,男性12例,女性38例,平均年龄(46.54±13.16)岁。RA缓解组患者50例,男性10例,女性40例；平均年龄(41.82±14.34)岁。正常对照组30例,男性10例,女性20例；平均年龄(43.03±13.35)岁。RA活动组、RA缓解组及正常对照组三组之间在年龄及性别构成等方面均无统计学差异(P均>0.05)。
2.RA活动组患者血清Clq、SAA和IL-6的水平分别为(27.32±8.31)mg/dl、(2953.91±874.17) μg/ml、(78.06±36.22) pg/ml, RA缓解组患者血清C1q, SAA和IL-6的水平分别为(22.41±4.91)mg/dl、(211.91±52.56)μg/ml、(5.47±1.65) pg/ml,正常对照组血清C1q, SAA和IL-6的水平分别为(16.62±4.86) mg/dl、(185.08±61.38)μg/ml、(2.38±0.47) pg/ml,RA患者活动组Clq水平高于缓解组和正常对照组,缓解组Clq水平高于正常对照组,差异具有统计学意义(P<0.05),RA患者活动组SAA和IL-6水平高于缓解组和正常对照组,差异具有统计学意义(P<0.05),RA患者缓解组SAA和IL-6水平与正常对照组相比无统计学意义(P>0.05)。
结论
1.RA活动期患者血清C1q、SAA及IL-6的水平均有高表达,RA患者体内C1q、SAA及IL-6水平的变化与RA疾病的活动度有关,它们可能成为RA病情监测和疗效判断的临床指标。
2. C1q、SAA及IL-6在RA的发生、发展过程中起着重要作用,探讨三者在RA发病机制中的作用,有利于观察RA的治疗效果,从而更好地指导RA的临床治疗。
Rheumatoid arthritis(RA) is a common difficult and baffling diseases in clinic, it is a chronic and progressive autoimmune disease(AID). Its etiology is unknown so far,and may be associated with heredity, endocrine, geography, occupation, nutrition, bacteria and virus infection,and psychological and social environment difference factors.The main clinical manifestations of RA include chronic, symmetry and many synovial arthritis and the extra-articular changes. Clinically, the disease occurs in the hand, wrist, feet and other small joints,it attacks recurrently and shows symmetric distribution.In the early stage，joint manifests swelling and pain,then articular cartilage is damaged and joint space narrows down,in the late stage, serious bone destruction and absorption lead to joint rigidity, deformity, dysfunction.The disease shows poor prognosis and has a high probability of disability.
Clinically,the judgment of pathological changes degree and activities of RA has great significance for the diagnosis and treatment and prognosis.All the time, the evaluation indictor,which evaluates early diagnosis and disease severity of RA,is the research hotspot problem.At present,the disease activity evaluation of RA needs to comprehensive judgment by many factors in clinic,such as the number of joint swelling,pain and tenderness joint number,morning stiffness time, C-reaction protein (CRP), erythrocyte sedimentation rate(ESR) and so on,disease activity score(DAS) rating system is currently the most widely used evaluation standard among the evaluation standards. In recent years, with the continuous improvement of instrument and inspection technique, the measurement of inflammation marker is also more and more be taken seriously,Clinicians hope to find more sensitive and specific inflammation marker, in order to provide better service for clinic.
Clq as the promoter of complement classic activation pathway, it plays an important role in preventing tissue autoimmune injury and clearing circulating immune complexes in vivo.At present, the research about Clq is mainly concentrated in patients with systemic lupus erythematosus,but in patients with RA is rarely founded. Serum amyloid A protein(SAA) is an acute phase protein, belongs to heterogeneous class protein of the apolipoprotein family, its relative molecular weight is about12000. In the acute phase reaction, SAA content increased sharply, the research found that serum amyloid A protein is most closely related to disease activity in the case of suffering from inflammatory arthritis. Related studies have shown that elevated serum SAA levels in patients with RA, and better reflect the activity of RA. However, the role of SAA in the pathogenesis of RA is not clear, so it needs to continue to discuss. RA is a chronic immune-mediated inflammatory diseases, its inflammation and tissue injury involves a variety of inflammatory cytokines, abnormal expression of various inflammatory factors play an important role in the progression of RA. The study found that lnterleukin-6(IL-6) is mainly produced by activated monocytes. It is one of the important mediators of synovial inflammation and joint injury of RA. Related studies have shown that IL-6levels increase in serum of patients with with RA in active stage, and is related to some indicators of disease activity. Therefore, this study intends to detect C1q,SAA and IL-6levels of different periods in the serum of patients with RA, and compares their levels with that of the normal control group,in order to investigate clinical significance of changes of the three levels of different periods in patients with RA.
Materials and Methods
1. Clinical data and methods
We collect50blood specimens of patients with RA in active stage and inactive stage respectively, all the RA patients fulfilled the American College of Rheumatology (ARA) revised criteria for classification in1987, and we also collect30healthy human blood specimens, then store them at-80℃refrigerator after centrifugation, our purpose is to detect Clq, SAA and IL-6levels in serum of the three groups.We use Roche P-800automatic biochemical analyzer produced by Germany Roche and Clq reagent produced by Shanghai Beijia biochemical reagent Co, Ltd to detect serum C1q levels by immunoturbidimetric assay(ITA).We use Roche cobas8000automatic biochemical analyzer and IL-6reagent produced by Germany Roche to detect serum IL-6levels by electro chemiluminescence(ECL) method. We use Multiskan Mk3type microplate reader produced by Shanghai Thermo Fisher Scientific Insrument Co, Ltd and SAA kit produced by the United States R&D company to detect serum SAA levels by enzyme-linked immunosorbent assay(ELISA) method. All operations are strictly operated according to the kit instructions.
2. Statistical analysis
The SPSS17.0statistical software package was used for statistical analysis.The measurement data were expressed by mean±standard deviation(x±s),the groups were compared by one-way ANOVA analysis, P value<0.05was considered significant.
Results
1In the group of50patients with RA in active stage,12subjects were male,38subjects were female,the mean age was (46.54±13.16) years old. In the group of50patients with RA in inactive stage,10subjects were male,40subjects were female, the mean age was (41.82±14.34) years old. In the group of30normal controls,10subjects were male,20subjects were female, the mean age was (43.03±13.35) years old. There were no statistical differences among the three groups in age and gender (P>0.05).
2The serum levels of C1q,SAA and IL-6in the group of patients with RA in active stage were (27.32±8.31) mg/dl、(2953.91±874.17) μg/ml、(78.06±36.22) pg/ml, the serum levels of C1q,SAA and IL-6in the group of patients with RA in inactive stage were (22.41±4.91) mg/dl、(211.91±52.56)μg/dl、(5.47±1.65) pg/ml, the serum levels of C1q,SAA and IL-6in the group of normal controls were (16.62±4.86) mg/dl、(185.08±61.38)μg/ml、(2.38±0.47) pg/ml. The serum Clq levels in the group of patients with RA in active stage was higher than that in the group of patients with RA in inactive stage and the normal control group, the serum Clq levels in the group of patients with RA in inactive stage was higher than that in the normal control group, and it has the statistical Signifcance (P<0.05), the serum SAA and IL-6levels in the group of patients with RA in active stage were higher than those in the group of patients with RA in inactive stage and the normal control group, and it has the statistical Signifcance (P<0.05), there were no statistical differences between the group of patients with RA in inactive stage and the normal control group in the serum SAA and IL-6levels(P>0.05).
Conclusions
1The serum levels of Clq, SAA and IL-6are highly expressed in the serum of patients with RA in active stage. The changes of serum C1q、SAA and IL-6levels in patients with RA have relations with the disease activity of RA, and they may become the clinical indicators of condition monitoring and curative effect assessment of patients with RA.
2Clq, SAA and IL-6play an important role in the occurrence and development process of RA.Discussing the role of the three in the pathogenesis of RA may be beneficial for observing the therapeutic effect of RA,so as to better guide the clinical treatment opf RA
引文
[1]Firestein GS.Evolving concepts of rheumatoid arthritis[J]. Nature,2003; 423(6937):356-61
[2]Gabriel SE.The epidemiology of rheumatoid arthritis[J]. Rheum Dis Clin North Am,2001; 27 (2):269～81
[3]张乃峥,R.Wigley,曾庆徐,等.关于某些风湿性疾病在中国流行情况的调查[J].中华内科杂志,1995；34(2)：79-83
[4]Brenner M, Meng HC, Yarlett NC, et al. The non-MHC quantitative trait locus Cia5 contains three major arthritis genes that differentially regulate disease severity, pannus formation, and joint damage in collagen-and pristane-induced arthritis[J]. Immunol, 2005; 174 (12):7894-903
[5]刘栩,贾园,安媛,等.类风湿关节炎患者发病形式和临床特点的现况调查[J].中日友好医院学报,2008；22(5)：266-269
[6]Kim SK,Bae J,Lee H, et al. Greater prevalence of seropositivity for anti-cyclic citrullinated peptide antibody in unaffected first-degree relatives in multicase rheumatoid arthritis-affected families[J]. Korean J Intern Med,2013; 28 (1):45-53
[7]Vittecoq O,Incaurgarat B,Jouen-Beades F, et alAutoantibodies recognizing citrullinated rat filaggrin in an ELISA using citrullinated and non-citrullinated recombinant proteins as antigens are highly diagnostic for rheumatoid arthritis[J]. Clin Exp Immunol,2004; 135(1):173-80
[8]Nogueira L,Sebbag M,Vincent C, et al.Performance of two ELISA for antifilaggrin autoantibodies,using either affinity purified or deiminated recombinant human filaggrin,in the diagnosis of rheumatoid arthritis[J]. Ann Rheum Dis,2001; 60 (9):882-7
[9]Taraborelli M, Inverardi F, Fredi M, et al. Anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus patients with articular involvement:a predictive marker for erosive disease[J]. Reumatismo,2012;64(5):321-5
[10]Grootenboer-Mignot S, Nicaise-Roland P, Delaunay C, et al. Second generation anti-cyclic citrullinated peptide (anti-CCP2) antibodies can replace other anti-filaggrin antibodies and improve rheumatoid arthritis diagnosis[J]. Scand J Rheumatol,2004;33(4):218-20
[11]Galati S, Beauvillain C, Renier G, et al. Comparison and relevance of rheumatoid factors, antikeratin antibodies and anti-cyclic citrullinated peptides antibodies in rheumatoid arthritis[J]. Ann Biol Clin,2008;66(2):157-64
[12]Manivelavan D, C K V. Anti-cyclic citrullinated Peptide antibody:an early diagnostic and prognostic biomarker of rheumatoid arthritis[J]. J Clin Diagn Res,2012;6(8):1393-6
[13]Rho Y H, Chung C P, Oeser A, et al. Inflammatory mediators and premature coronary at heros clerosis in rheumatoid arthritis[J]. Arthritis Rheum,2009; 61:1580-1585
[14]Pierce B L, Ballard-Barbash R, Bernstein L, et al. Elevated biomarkers of inflammation are associated with reduced survival ammong breast cancer patients[J]. J Clin Oncol,2009; 27:3437-3444
[15]Li T, Huang Z, Zheng B, et al. Serum disease-associated proteins of ankylosing spondylitis: results of a preliminary study by comparative proteomics[J]. Clin Exp Rheumatol,2010; 28:201-207
[16]6 Hara R, Murphy EP, Whitehead AS, et al. Acute-phase serum amyloid A production by rheumatoid arthritis synovial tissue[J]. Arthritis Res,2000;2:142-144
[17]Li TW, Zheng BR, Huang ZX, et al. Screening disease-associated proteins from sera of patients with rheumatoidarthritis:a comparative proteomic study[J]. Chin Med J, 2010;123:537-543
[18]杨平,梁军,邓剑.类风湿性关节炎患者两种急性时相蛋白检测的临床价值[J].现代预防医学,2007；34(20)：3972-3973
[19]Amett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis[J]. Arthritis Rheum, 1988; 31 (3):315-24
[20]Walport MJ. Complement. Second of two parts[J]. N Engl J Med,2001; 344(15):1140-4
[21]Walport MJ. Complement. First of two parts[J]. N Engl J Med.,2001; 344(14):1058-66
[22]Harboe M, Mollnes TE. The alternative complement pathway revisited[J]. J Cell Mol Med, 2008; 12(4):1074-84
[23]Spitzer D, Mitchell LM, Atkinson JP, et al. Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly [J]. J Immunol,2007; 179(4):2600-8
[24]Kemper C, Hourcade DE. Properdin:New roles in pattern recognition and target clearance[J]. Mol Immunol,2008; 45(16):4048-56
[25]Hietala MA, Nandakumar KS, Persson L,et al. Complement activation by both classical and alternative pathways is critical for the effector phase of arthritis[J]. Eur J Immunol, 2004; 34(4):1208-16
[26]Neumann E, Barnum SR, Tamer IH,et al. Local production of complement proteins in rheumatoid arthritis synovium[J]. Arthritis Rheum,2002; 46(4):934-45
[27]Trouw LA, Haisma EM, Levarht EW,et al. Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways[J]. Arthritis Rheum.,2009; 60(7):1923-31
[28]Biro E, Nieuwland R, Tak PP,et al. Activated complement components and complement activator molecules on the surface of cell-derived microparticles in patients with rheumatoid arthritis and healthy individuals[J]. Ann Rheum Dis,2007; 66(8):1085-92
[29]SjobergAP, Trouw LA, Blom AM. Complement activation and inhibition:a delicate balance[J]. Trends Immunol,2009; 30 (2):83-90
[30]杨琴,张岩,于本章.Clq抗原/Clq抗体与系统性红斑狼疮疾病研究进展[J].医学检验与临床,2010；21(4)：99-107
[31]Ghai R, Waters P, Roumenina LT, et al. Clq and its growing family[J]. Immunobiology, 2007; 212 (4-5):253-66
[32]Wouters D, Voskuyl AE, Molenaar ET, et al. Evaluation of classical complement pathway activation in rheumatoid arthritis:measurement of Clq-C4 complexes as novel activation products[J]. Arthritis Rheum,2006; 54 (4):1143-50
[33]丁振若,于文彬,苏明权,等.现代检验医学[M].北京：人民军医出版社,2007：824-825
[34]O'Hara R, Murphy EP, Whitehead AS,et al. Acute-phase serum amyloid A production by rheumatoid arthritis synovial tissue[J]. Arthritis Res,2000;2(2):142-4
[35]]Cunnane G. Amyloid precursors and amyloidosis in inflammatory arthritis[J]. Curr Opin Rheumatol,2001;13(1):67-73
[36]Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant[J]. Eur J Biochem,1999;265(2):501-23
[37]Cunnane G, Grehan S, Geoghegan S,et al. Serum amyloid A in the assessment of early inflammatory arthritis[J]. J Rheumatol,2000;27(1):58-63
[38]刘钢,王兰兰,李立新,等.血清淀粉样蛋白A-类风湿关节炎的一个炎性指标[J].中华风湿病学杂志,2002；6(2)：108-110
[39]梁敏坚,胡波,李朝霞,等.类风湿性关节炎患者SAA水平变化的初步探讨[J].临床检验杂志,2001；19(2)：114
[40]de Seny D, Fillet M, Meuwis MA,et al. Discovery of new rheumatoid arthritis biomarkers using the surface-enhanced laser desorption/ionization time-of-flight mass spectrometry ProteinChip approach[J]. Arthritis Rheum,2005;52(12):3801-12
[41]张欣,类风湿关节炎患者血清蛋白质组学研究[D].[博士学位论文],北京：中国协和医科大学,2008.
[42]张炎,类风湿关节炎患者血清蛋白质组学研究[D].[博士学位论文],北京：北京协和医学院,2009.
[43]Furlaneto CJ, Campa A. A novel function of serum amyloid A:a potent stimulus for the release of tumor necrosis factor-alpha, interleukin-lbeta, and interleukin-8 by human blood neutrophil[J]. Biochem Biophys Res Commun,2000;268(2):405-8
[44]Sandri S, Rodriguez D, Gomes E,et al. Is serum amyloid A an endogenous TLR4 agonist? [J]. J Leukoc Biol,2008;83(5):1174-80
[45]Hatanaka E, Pereira Ribeiro F, Campa A. The acute phase protein serum amyloid A primes neutrophils[J]. FEMS Immunol Med Microbiol,2003; 38(1):81-4
[46]Koga T, Torigoshi T, Motokawa S,et al. Serum amyloid A-induced IL-6 production by rheumatoid synoviocytes[J]. FEBS Lett,2008;582(5):579-85
[47]Michaeli A, Finci-Yeheskel Z, Dishon S,et al. Serum amyloid A enhances plasminogen activation:implication for a role in colon cancer[J]. Biochem Biophys Res Commun,2008;368(2):368-73
[48]Hatanaka E, Monteagudo PT, Marrocos MS,et al. Interaction between serum amyloid A and leukocytes-a possible role in the progression of vascular complications in diabetes[J]. Immunol Lett,2007;108(2):160-6
[49]Tarqonska-Stepniak B, Dryglewska M, Majdan M. Influence of long-term leflunomide treatment on serum amyloid concentration in rheumatoid arthritis patients[J].Pharmacol Rep,2010; 62 (4):719-25
[50]Nishimoto N. Interleukin-6 in rheumatoid arthritis[J]. Curr Opin Rheumatol, 2006;18(3):277-81
[51]Nakahara H, Song J, Sugimoto M,et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis[J]. Arthritis Rheum,2003;48(6):1521-9
[52]Van Bezooijen RL, Van Der Wee-Pals L, Papapoulos SE,et al. Interleukin 17 synergises with tumour necrosis factor alpha to induce cartilage destruction in vitro[J]. Ann Rheum Dis,2002;61(10):870-6
[53]Lubberts E, Koenders MI, van den Berg WB. The role of T-cell interleukin-17 in conducting destructive arthritis:lessons from animal models[J]. Arthritis Res Ther,2005;7(1):29-37
[54]Torikai E, Kageyama Y, Takahashi M,et al. The effect of methotrexate on bone metabolism markers in patients with rheumatoid arthritis[J]. Mod Rheumatol,2006;16(6):350-4
[55]Korczowska I, Lacki JK, Hrycaj P. Influence of infliximab on cytokines network and markers of bone remodeling in rheumatoid arthritis patients[J]. Yonsei Med J, 2013;54(1):183-8
[56]Bettelli E, Carrier Y, Gao W,et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells[J]. Nature,2006;441(7090):235-8
[57]Mangan PR, Harrington LE, O'Quinn DB,et al. Transforming growth factor-beta induces development of the T(H)17 lineage[J]. Nature,2006;441 (7090):231-4
[58]Dessein PH. Joffe BL, Singh S. Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis[J]. Arthritis Res Ther,2005; 7 (3) R634-43
[1]Sellar GC, Blake DJ, Reid KB. Characterization and organization of the genes encoding the A-, B-and C-chains of human complement subcomponent Clq. The complete derived amino acid sequence of human Clq[J]. Biochem J,1991;274 (Pt 2):481-90
[2]Kishore U, Reid KB. Clq:structure, function, and receptors[J]. Immunopharmacology, 2000;49(l-2):159-70
[3]Kishore U, Gupta SK, Perdikoulis MV,et al. Modular organization of the carboxyl-terminal, globular head region of human Clq A, B, and C chains[J]. J Immunol,2003;171(2):812-20
[4]Kishore U, Ghai R, Greenhough TJ,et al. Structural and functional anatomy of the globular domain of complement protein Clq[J]. Immunol Lett,2004;95 (2):113-28
[5]Kojouharova MS, Gadjeva MG, Tsacheva IG,et al. Mutational analyses of the recombinant globular regions of human Clq A, B, and C chains suggest an essential role for arginine and histidine residues in the Clq-IgG interaction [J]. J Immunol,2004;172(7):4351-8
[6]Gadjeva MG, Rouseva MM, Zlatarova AS,et al. Interaction of human Clq with IgG and IgM:revisited[J]. Biochemistry,2008;47(49):13093-102
[7]Zlatarova AS, Rouseva M, Roumenina LT,et al. Existence of different but overlapping IgG-and IgM-binding sites on the globular domain of human Clq[J]. Biochemistry,2006;45(33): 9979-88
[8]Nauta AJ, Trouw LA, Daha MR,et al. Direct binding of Clq to apoptotic cells and cell blebs induces complement activation [J]. Eur J Immunol,2002; 32(6):1726-36
[9]Roos A, Xu W, Castellano G,et al. A pivotal role for innate immunity in the clearance of apoptotic cells[J]. Eur J Immunol,2004;34(4):921-9
[10]Navratil JS, Watkins SC, Wisnieski JJ,et al. The globular heads of Clq specifically recognize surface blebs of apoptotic vascular endothelial cells[J]. J Immunol,2001; 166(5): 3231-9
[11]Zwart B, Ciurana C, Rensink I,et al. Complement activation by apoptotic cells occurs predominantly via IgM and is limited to late apoptotic (secondary necrotic) cells[J]. Autoimmunity,2004;37(2):95-102
[12]Sjoberg AP, Manderson GA, Morgelin M,et al. Short leucine-rich glycoproteins of the extracellular matrix display diverse patterns of complement interaction and activation[J]. Mol Immunol,2009;46(5):830-9
[13]Danesh J, Wheeler JG, Hirschfield GM,et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease[J]. N Engl J Med,2004; 350(14):1387-97
[14]Erlinger TP, Platz EA, Rifai N,et al. C-reactive protein and the risk of incident colorectal cancer[J]. JAMA,2004;291(5):585-90
[15]Biro A, Rovo Z, Papp D,et al. Studies on the interactions between C-reactive protein and complement proteins[J]. Immunology,2007;121(1):40-50
[16]McGrath FD, Brouwer MC, Arlaud GJ,et al. Evidence that complement protein Clq interacts with C-reactive protein through its globular head region[J]. J Immunol,2006; 176(5):2950-7
[17]Biro A, Thielens NM, Cervenak L,et al. Modified low density lipoproteins differentially bind and activate the C1 complex of complement[J]. Mol Immunol,2007;44(6):1169-77
[18]Biro A, Ling WL, Arlaud GJ. Complement protein Clq recognizes enzymatically modified low-density lipoprotein through unesterified fatty acids generated by cholesterol esterase[J]. Biochemistry,2010;49(10):2167-76
[19]Kawai Y, Saito A, Shibata N,et al. Covalent binding of oxidized cholesteryl esters to protein:implications for oxidative modification of low density lipoprotein and atherosclerosis[J]. J Biol Chem,2003;278(23):21040-9
[20]Yin W, Ghebrehiwet B, Weksler B,et al. Classical pathway complement activation on human endothelial cells[J]. Mol Immunol,2007;44(9):2228-34
[21]Peerschke El, Yin W, Grigg SE,et al. Blood platelets activate the classical pathway of human complement[J]. J Thromb Haemost,2006;4(9):2035-42
[22]Peerschke El, Yin W, Alpert DR,et al. Serum complement activation on heterologous platelets is associated with arterial thrombosis in patients with systemic lupus erythematosus and antiphospholipid antibodies[J]. Lupus,2009; 18(6):530-8
[23]Roumenina LT, Popov KT, Bureeva SV,et al. Interaction of the globular domain of human Clq with Salmonella typhimurium lipopolysaccharide[J]. Biochim Biophys Acta,2008;1784(9):1271-6
[24]Bonaparte RS, Hair PS, Banthia D,et al. Human astrovirus coat protein inhibits serum complement activation via C1, the first component of the classical pathway[J]. J Virol,2008; 82(2):817-27
[25]Hair PS, Gronemus JQ, Crawford KB,et al. Human astrovirus coat protein binds Clq and MBL and inhibits the classical and lectin pathways of complement activation[J]. Mol Immunol,2010;47(4):792-8
[26]Oberkersch R, Attorresi AI, Calabrese GC. Low-molecular-weight heparin inhibition in classical complement activation pathway during pregnancy [J]. Thromb Res,2010; 125(5): e240-5
[27]Nayak A, Ferluga J, Tsolaki AG,et al. The non-classical functions of the classical complement pathway recognition subcomponent Clq[J]. Immunol Lett,2010;131(2): 139-50
[28]Farber K, Cheung G, Mitchell D,et al. Clq, the recognition subcomponent of the classical pathway of complement, drives microglial activation[J]. J Neurosci Res,2009;87(3): 644-52
[29]Fraser DA, Pisalyaput K, Tenner AJ. Clq enhances microglial clearance of apoptotic neurons and neuronal blebs, and modulates subsequent inflammatory cytokine production [J]. J Neurochem,2010;112(3):733-43
[30]Bonifati DM, Kishore U. Role of complement in neurodegeneration and neuroinflammation[J]. Mol Immunol,2007;44(5):999-1010
[31]Stevens B, Allen NJ, Vazquez LE,et al. The classical complement cascade mediates CNS synapse elimination[J]. Cell,2007;131(6):1164-78
[32]Csomor E, Bajtay Z, Sandor N,et al. Complement protein C1q induces maturation of human dendritic cells[J]. Mol Immunol,2007;44(13):3389-97
[33]Castellano G, Woltman AM, Schlagwein N,et al. Immune modulation of human dendritic cells by complement[J]. Eur J Immunol,2007;37(10):2803-11
[34]van Montfoort N, de Jong JM, Schuurhuis DH,et al. A novel role of complement factor C1q in augmenting the presentation of antigen captured in immune complexes to CD8+T lymphocytes[J]. J Immunol,2007;178 (12):7581-6
[35]Yurasov S, Wardemann H, Hammersen J,et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus[J]. J Exp Med,2005;201 (5):703-11
[36]Groeneveld TW, Oroszlan M, Owens RT,et al. Interactions of the extracellular matrix proteoglycans decorin and biglycan with Clq and collectins[J], J Immunol,2005;175(7): 4715-23
[37]Fraser DA, Laust AK, Nelson EL,et al. C1q differentially modulates phagocytosis and cytokine responses during ingestion of apoptotic cells by human monocytes, macrophages, and dendritic cells[J]. J Immunol,2009;183 (10):6175-85
[38]Ogden CA, deCathelineau A, Hoffmann PR,et al. C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinoc-ytosis and uptake of apoptotic cells[J]. J Exp Med,2001;194(6):781-95
[39]Ghebrehiwet B, Lim BL, Peerschke EI,et al. Isolation, cDNA cloning, and overexpression of a 33-kD cell surface glycoprotein that binds to the globular "heads" of C1q[J]. J Exp Med,1994;179(6):1809-21
[40]Ghebrehiwet B, Peerschke El. cC1q-R (calreticulin) and gC1q-R/p33:ubiquitously expressed multi-ligand binding cellular proteins involved in inflammation and infection[J]. Mol Immunol,2004;41(2-3):173-83
[41]Peterson KL, Zhang W, Lu PD,et al. The Clq-binding cell membrane proteins cC1q-R and gC1q-R are released from activated cells:subcellular distribution and immunochemical characterization[J]. Clin Immunol Immunopathol,1997; 84(1):17-26
[42]Dedio J, Jahnen-Dechent W, Bachmann M,et al. The multiligand-binding protein gC1qR, putative C1q receptor, is a mitochondrial protein[J]. J Immunol,1998;160(7):3534-42
[43]Lim BL, Reid KB, Ghebrehiwet B,et al. The binding protein for globular heads of complement C1q, gC1qR. Functional expression and characterization as a novel vitronectin binding factor[J]. J Biol Chem,1996;271(43):26739-44
[44]Fausther-Bovendo H, Vieillard V, Sagan S,et al. HIV gp41 engages gC1qR on CD4+T cells to induce the expression of an NK ligand through the PIP3/H2O2 pathway[J]. PLoS Pathog,2010;6:e1000975
[45]Peerschke El, Ghebrehiwet B. The contribution of gC1qR/p33 in infection and inflammation[J]. Immunobiology,2007;212(4-5):333-42
[46]Gardai SJ, Xiao YQ, Dickinson M,et al. By binding SIRPalpha or calreticulin/CD91, lung collectins act as dual function surveillance molecules to suppress or enhance inflammation[J]. Cell,2003;115(1):13-23
[47]Michalak M, Corbett EF, Mesaeli N,et al. Calreticulin:one protein, one gene, many functions[J]. Biochem J,1999;344(Pt 2):281-92
[48]Gregory CD, Devitt A. The macrophage and the apoptotic cell:an innate immune interaction viewed simplistically[J]. Immunology,2004;113(1):1-14
[49]Vegh Z, Kew RR, Gruber BL,et al. Chemotaxis of human monocyte-derived dendritic cells to complement component Clq is mediated by the receptors gC1qR and cC1qR[J]. Mol Immunol,2006;43(9):1402-7
[50]Fonseca MI, Carpenter PM, Park M,et al. C1qR(P), a myeloid cell receptor in blood, is predominantly expressed on endothelial cells in human tissue[J]. J Leukoc Biol,2001;70(5): 793-800
[51]Nepomuceno RR, Ruiz S, Park M,et al. C1qRP is a heavily O-glycosylated cell surface protein involved in the regulation of phagocytic activity[J]. J Immunol,1999;162(6): 3583-9
[52]McGreal E, Gasque P. Structure-function studies of the receptors for complement Clq[J]. Biochem Soc Trans,2002;30(Pt 6):1010-4
[53]Eggleton P, Tenner AJ, Reid KB. C1q receptors[J]. Clin Exp Immunol,2000;120(3):406-12
[54]Duus K, Hansen EW, Tacnet P,et al. Direct interaction between CD91 and Clq[J]. FEBS J, 2010;277(17):3526-37
[55]Trouw LA, Blom AM, Gasque P. Role of complement and complement regulators in the removal of apoptotic cells[J]. Mol Immunol,2008;45(5):1199-207
[56]Sjoberg AP, Trouw LA, Blom AM. Complement activation and inhibition:a delicate balance[J]. Trends Immunol,2009;30(2):83-90
[57]Hietala MA, Nandakumar KS, Persson L,et al. Complement activation by both classical and alternative pathways is critical for the effector phase of arthritis[J]. Eur J Immunol, 2004;34(4):1208-16
[58]Shingu M, Watanabe Y, Tomooka K,et al. Complement degradation products in rheumatoid arthritis synovial fluid[J]. Br J Rheumatol,1994;33(3):299-300
[59]Neumann E, Barnum SR, Tamer IH,et al. Local production of complement proteins in rheumatoid arthritis synovium[J]. Arthritis Rheum,2002;46(4):934-45
[60]Wouters D, Voskuyl AE, Molenaar ET,et al. Evaluation of classical complement pathway activation in rheumatoid arthritis:measurement of Clq-C4 complexes as novel activation products[J]. Arthritis Rheum,2006;54(4):1143-50
[61]Konttinen YT, Ceponis A, Meri S,et al. Complement in acute and chronic arthritides: assessment of C3c, C9, and protectin (CD59) in synovial membrane[J]. Ann Rheum Dis, 1996;55(12):888-94
[62]Kurreeman FA, Padyukov L, Marques RB,et al. A candidate gene approach identifies the TRAF1/C5 region as a risk factor for rheumatoid arthritis[J]. PLoS Med,2007;4(9):e278
[63]Molenaar ET, Voskuyl AE, Familian A,et al. Complement activation in patients with rheumatoid arthritis mediated in part by C-reactive protein[J]. Arthritis Rheum,2001;44(5): 997-1002
[64]Merlini G, Bellotti V. Molecular mechanisms of amyloidosis[J]. N Engl J Med, 2003;349(6):583-96
[65]Westermark P, Benson MD, Buxbaum JN,et al. Amyloid fibril protein nomenclature[J]. Amyloid,2002;9(3):197-200
[66]Tuglular S, Yalcinkaya F, Paydas S,et al. A retrospective analysis for aetiology and clinical findings of 287 secondary amyloidosis cases in Turkey[J]. Nephrol Dial Transplant, 2002;17(11):2003-5
[67]Hazenberg BP, van Gameren Ⅱ, Bijzet J,et al. Diagnostic and therapeutic approach of systemic amyloidosis[J]. Neth J Med,2004;62(4):121-8
[68]Tanaka F, Migita K, Honda S,et al. Clinical outcome and survival of secondary (AA) amyloidosis[J]. Clin Exp Rheumatol,2003;21(3):343-6
[69]Joss N, McLaughlin K, Simpson K,et al. Presentation, survival and prognostic markers in AAamyloidosis[J]. QJM,2000;93(8):535-42
[70]Gillmore JD, Lovat LB, Persey MR,et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein[J]. Lancet, 2001;358(9275):24-9
[71]Bellotti V, Chiti F. Amyloidogenesis in its biological environment:challenging a fundamental issue in protein misfolding diseases[J]. Curr Opin Struct Biol,2008;18(6): 771-9
[72]Merlini G, Seldin DC, Gertz MA. Amyloidosis:pathogenesis and new therapeutic options[J]. J Clin Oncol,2011;29(14):1924-33
[73]Uversky VN. Mysterious oligomerization of the amyloidogenic proteins[J]. FEBS J, 2010;277(14):2940-53
[74]Sakono M, Zako T. Amyloid oligomers:formation and toxicity of Abeta oligomers[J]. FEBS J,2010;277(6):1348-58
[75]Stix B, Kahne T, Sletten K,et al. Proteolysis of AA amyloid fibril proteins by matrix metalloproteinases-1,-2, and-3[J]. Am J Pathol,2001;159(2):561-70
[76]van der Hilst JC, Yamada T, Op den Camp HJ,et al. Increased susceptibility of serum amyloid A 1.1 to degradation by MMP-1:potential explanation for higher risk of type AA amyloidosis[J]. Rheumatology (Oxford),2008;47(11):1651-4
[77]Elimova E, Kisilevsky R, Szarek WA,et al. Amyloidogenesis recapitulated in cell culture:a peptide inhibitor provides direct evidence for the role of heparan sulfate and suggests a new treatment strategy[J]. FASEB J,2004;18(14):1749-51
[78]Li JP, Galvis ML, Gong F,et al. In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis [J]. Proc Natl Acad Sci USA,2005;102(18):6473-7
[79]Ma B, Nussinov R. Selective molecular recognition in amyloid growth and transmission and cross-species barriers[J]. J Mol Biol,2012;421(2-3):172-84
[80]Larsson A, Malmstrom S, Westermark P. Signs of cross-seeding:aortic medin amyloid as a trigger for protein AA deposition[J]. Amyloid,2011;18(4):229-34
[81]Westermark GT, Westermark P. Serum amyloid A and protein AA:molecular mechanisms of a transmissible amyloidosis[J]. FEBS Lett,2009;583(16):2685-90
[82]Jucker M, Walker LC. Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders[J]. Ann Neurol,2011;70(4):532-40
[83]Sponarova J, Nystrom SN, Westermark GT. AA-amyloidosis can be transferred by peripheral blood monocytes[J]. PLoS One,2008;3(10):e3308
[84]Nakamura T, Higashi S, Tomoda K,et al. Significance of SAA1.3 allele genotype in Japanese patients with amyloidosis secondary to rheumatoid arthritis[J]. Rheumatology (Oxford),2006;45(1):43-9
[85]Lachmann HJ, Goodman HJ, Gilbertson JA,et al. Natural history and outcome in systemic AAamyloidosis[J]. N Engl J Med,2007;356(23):2361-71
[86]Nakamura T, Yamamura Y, Tomoda K,et al. Efficacy of cyclophosphamide combined with prednisolone in patients with AA amyloidosis secondary to rheumatoid arthritis[J]. Clin Rheumatol,2003;22(6):371-5
[87]Nakamura T. Clinical strategies for amyloid A amyloidosis secondary to rheumatoid arthritis[J]. Mod Rheumatol,2008;18(2):109-18
[88]Nakayamada S, Saito K, Nakatsuka K,et al. A case of rheumatoid arthritis with secondary amyloidosis in urinary bladder[J]. Ryumachi,2002;42(3):618-23
[89]Nakamura T, Yamamura Y, Tomoda K,et al. Massive hematuria due to bladder amyloidosis in patients with rheumatoid arthritis:three case reports[J]. Clin Exp Rheumatol,2003;21(5): 673-4
[90]Tanaka F, Migita K, Honda S,et al. Clinical outcome and survival of secondary (AA) amyloidosis[J]. Clin Exp Rheumatol,2003;21(3):343-6
[91]Rader DJ. Inflammatory markers of coronary risk[J]. N Engl J Med,2000; 343(16): 1179-82
[92]Bokarewa M, Abrahamson M, Levshin N,et al. Cystatin C binds serum amyloid A, downregulating its cytokine-generating properties[J]. J Rheumatol,2007;34 (6):1293-301
[93]Kurth I, Horsten U, Pflanz S,et al. Importance of the membrane-proximal extracellular domains for activation of the signal transducer glycoprotein 130[J]. J Immunol,2000; 164 (1):273-82
[94]Dillon SR, Sprecher C, Hammond A,et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice[J]. Nat Immunol,2004;5(7):752-60
[95]Pflanz S, Hibbert L, Mattson J,et al. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27[J]. J Immunol,2004;172(4):2225-31
[96]Emery P, Keystone E, Tony HP,et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals:results from a 24-week multicentre randomised placebo-controlled trial[J]. Ann Rheum Dis,2008;67(11):1516-23
[97]Heinrich PC, Behrmann I, Haan S,et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation [J]. Biochem J,2003;374(Pt 1):1-20
[98]Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease[J]. Cytokine Growth Factor Rev,2002;13(4-5):357-68
[99]Kishimoto T. IL-6:from its discovery to clinical applications[J]. Int Immunol,2010;22(5): 347-52
[100]Tanaka T, Kishimoto T. Targeting interleukin-6:all the way to treat autoimmune and inflammatory diseases[J]. Int J Biol Sci,2012;8(9):1227-36
[101]Hein GE, Kohler M, Oelzner P,et al. The advanced glycation end product pentosidine correlates to IL-6 and other relevant inflammatory markers in rheumatoid arthritis[J]. Rheumatol Int,2005;26(2):137-41
[102]Rooney T, Roux-Lombard P, Veale DJ,et al. Synovial tissue and serum biomarkers of disease activity, therapeutic response and radiographic progression:analysis of a proof-of-concept randomised clinical trial of cytokine blockade[J]. Ann Rheum Dis,2010;69 (4):706-14
[103]Choy E. Inhibiting interleukin-6 in rheumatoid arthritis[J]. Curr Rheumatol Rep,2008; 10(5):413-7
[2]Gabriel SE.The epidemiology of rheumatoid arthritis[J]. Rheum Dis Clin North Am,2001; 27 (2):269～81
[3]张乃峥,R.Wigley,曾庆徐,等.关于某些风湿性疾病在中国流行情况的调查[J].中华内科杂志,1995；34(2)：79-83
[4]Brenner M, Meng HC, Yarlett NC, et al. The non-MHC quantitative trait locus Cia5 contains three major arthritis genes that differentially regulate disease severity, pannus formation, and joint damage in collagen-and pristane-induced arthritis[J]. Immunol, 2005; 174 (12):7894-903
[5]刘栩,贾园,安媛,等.类风湿关节炎患者发病形式和临床特点的现况调查[J].中日友好医院学报,2008；22(5)：266-269
[6]Kim SK,Bae J,Lee H, et al. Greater prevalence of seropositivity for anti-cyclic citrullinated peptide antibody in unaffected first-degree relatives in multicase rheumatoid arthritis-affected families[J]. Korean J Intern Med,2013; 28 (1):45-53
[7]Vittecoq O,Incaurgarat B,Jouen-Beades F, et alAutoantibodies recognizing citrullinated rat filaggrin in an ELISA using citrullinated and non-citrullinated recombinant proteins as antigens are highly diagnostic for rheumatoid arthritis[J]. Clin Exp Immunol,2004; 135(1):173-80
[8]Nogueira L,Sebbag M,Vincent C, et al.Performance of two ELISA for antifilaggrin autoantibodies,using either affinity purified or deiminated recombinant human filaggrin,in the diagnosis of rheumatoid arthritis[J]. Ann Rheum Dis,2001; 60 (9):882-7
[9]Taraborelli M, Inverardi F, Fredi M, et al. Anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus patients with articular involvement:a predictive marker for erosive disease[J]. Reumatismo,2012;64(5):321-5
[10]Grootenboer-Mignot S, Nicaise-Roland P, Delaunay C, et al. Second generation anti-cyclic citrullinated peptide (anti-CCP2) antibodies can replace other anti-filaggrin antibodies and improve rheumatoid arthritis diagnosis[J]. Scand J Rheumatol,2004;33(4):218-20
[11]Galati S, Beauvillain C, Renier G, et al. Comparison and relevance of rheumatoid factors, antikeratin antibodies and anti-cyclic citrullinated peptides antibodies in rheumatoid arthritis[J]. Ann Biol Clin,2008;66(2):157-64
[12]Manivelavan D, C K V. Anti-cyclic citrullinated Peptide antibody:an early diagnostic and prognostic biomarker of rheumatoid arthritis[J]. J Clin Diagn Res,2012;6(8):1393-6
[13]Rho Y H, Chung C P, Oeser A, et al. Inflammatory mediators and premature coronary at heros clerosis in rheumatoid arthritis[J]. Arthritis Rheum,2009; 61:1580-1585
[14]Pierce B L, Ballard-Barbash R, Bernstein L, et al. Elevated biomarkers of inflammation are associated with reduced survival ammong breast cancer patients[J]. J Clin Oncol,2009; 27:3437-3444
[15]Li T, Huang Z, Zheng B, et al. Serum disease-associated proteins of ankylosing spondylitis: results of a preliminary study by comparative proteomics[J]. Clin Exp Rheumatol,2010; 28:201-207
[16]6 Hara R, Murphy EP, Whitehead AS, et al. Acute-phase serum amyloid A production by rheumatoid arthritis synovial tissue[J]. Arthritis Res,2000;2:142-144
[17]Li TW, Zheng BR, Huang ZX, et al. Screening disease-associated proteins from sera of patients with rheumatoidarthritis:a comparative proteomic study[J]. Chin Med J, 2010;123:537-543
[18]杨平,梁军,邓剑.类风湿性关节炎患者两种急性时相蛋白检测的临床价值[J].现代预防医学,2007；34(20)：3972-3973
[19]Amett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis[J]. Arthritis Rheum, 1988; 31 (3):315-24
[20]Walport MJ. Complement. Second of two parts[J]. N Engl J Med,2001; 344(15):1140-4
[21]Walport MJ. Complement. First of two parts[J]. N Engl J Med.,2001; 344(14):1058-66
[22]Harboe M, Mollnes TE. The alternative complement pathway revisited[J]. J Cell Mol Med, 2008; 12(4):1074-84
[23]Spitzer D, Mitchell LM, Atkinson JP, et al. Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly [J]. J Immunol,2007; 179(4):2600-8
[24]Kemper C, Hourcade DE. Properdin:New roles in pattern recognition and target clearance[J]. Mol Immunol,2008; 45(16):4048-56
[25]Hietala MA, Nandakumar KS, Persson L,et al. Complement activation by both classical and alternative pathways is critical for the effector phase of arthritis[J]. Eur J Immunol, 2004; 34(4):1208-16
[26]Neumann E, Barnum SR, Tamer IH,et al. Local production of complement proteins in rheumatoid arthritis synovium[J]. Arthritis Rheum,2002; 46(4):934-45
[27]Trouw LA, Haisma EM, Levarht EW,et al. Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways[J]. Arthritis Rheum.,2009; 60(7):1923-31
[28]Biro E, Nieuwland R, Tak PP,et al. Activated complement components and complement activator molecules on the surface of cell-derived microparticles in patients with rheumatoid arthritis and healthy individuals[J]. Ann Rheum Dis,2007; 66(8):1085-92
[29]SjobergAP, Trouw LA, Blom AM. Complement activation and inhibition:a delicate balance[J]. Trends Immunol,2009; 30 (2):83-90
[30]杨琴,张岩,于本章.Clq抗原/Clq抗体与系统性红斑狼疮疾病研究进展[J].医学检验与临床,2010；21(4)：99-107
[31]Ghai R, Waters P, Roumenina LT, et al. Clq and its growing family[J]. Immunobiology, 2007; 212 (4-5):253-66
[32]Wouters D, Voskuyl AE, Molenaar ET, et al. Evaluation of classical complement pathway activation in rheumatoid arthritis:measurement of Clq-C4 complexes as novel activation products[J]. Arthritis Rheum,2006; 54 (4):1143-50
[33]丁振若,于文彬,苏明权,等.现代检验医学[M].北京：人民军医出版社,2007：824-825
[34]O'Hara R, Murphy EP, Whitehead AS,et al. Acute-phase serum amyloid A production by rheumatoid arthritis synovial tissue[J]. Arthritis Res,2000;2(2):142-4
[35]]Cunnane G. Amyloid precursors and amyloidosis in inflammatory arthritis[J]. Curr Opin Rheumatol,2001;13(1):67-73
[36]Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant[J]. Eur J Biochem,1999;265(2):501-23
[37]Cunnane G, Grehan S, Geoghegan S,et al. Serum amyloid A in the assessment of early inflammatory arthritis[J]. J Rheumatol,2000;27(1):58-63
[38]刘钢,王兰兰,李立新,等.血清淀粉样蛋白A-类风湿关节炎的一个炎性指标[J].中华风湿病学杂志,2002；6(2)：108-110
[39]梁敏坚,胡波,李朝霞,等.类风湿性关节炎患者SAA水平变化的初步探讨[J].临床检验杂志,2001；19(2)：114
[40]de Seny D, Fillet M, Meuwis MA,et al. Discovery of new rheumatoid arthritis biomarkers using the surface-enhanced laser desorption/ionization time-of-flight mass spectrometry ProteinChip approach[J]. Arthritis Rheum,2005;52(12):3801-12
[41]张欣,类风湿关节炎患者血清蛋白质组学研究[D].[博士学位论文],北京：中国协和医科大学,2008.
[42]张炎,类风湿关节炎患者血清蛋白质组学研究[D].[博士学位论文],北京：北京协和医学院,2009.
[43]Furlaneto CJ, Campa A. A novel function of serum amyloid A:a potent stimulus for the release of tumor necrosis factor-alpha, interleukin-lbeta, and interleukin-8 by human blood neutrophil[J]. Biochem Biophys Res Commun,2000;268(2):405-8
[44]Sandri S, Rodriguez D, Gomes E,et al. Is serum amyloid A an endogenous TLR4 agonist? [J]. J Leukoc Biol,2008;83(5):1174-80
[45]Hatanaka E, Pereira Ribeiro F, Campa A. The acute phase protein serum amyloid A primes neutrophils[J]. FEMS Immunol Med Microbiol,2003; 38(1):81-4
[46]Koga T, Torigoshi T, Motokawa S,et al. Serum amyloid A-induced IL-6 production by rheumatoid synoviocytes[J]. FEBS Lett,2008;582(5):579-85
[47]Michaeli A, Finci-Yeheskel Z, Dishon S,et al. Serum amyloid A enhances plasminogen activation:implication for a role in colon cancer[J]. Biochem Biophys Res Commun,2008;368(2):368-73
[48]Hatanaka E, Monteagudo PT, Marrocos MS,et al. Interaction between serum amyloid A and leukocytes-a possible role in the progression of vascular complications in diabetes[J]. Immunol Lett,2007;108(2):160-6
[49]Tarqonska-Stepniak B, Dryglewska M, Majdan M. Influence of long-term leflunomide treatment on serum amyloid concentration in rheumatoid arthritis patients[J].Pharmacol Rep,2010; 62 (4):719-25
[50]Nishimoto N. Interleukin-6 in rheumatoid arthritis[J]. Curr Opin Rheumatol, 2006;18(3):277-81
[51]Nakahara H, Song J, Sugimoto M,et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis[J]. Arthritis Rheum,2003;48(6):1521-9
[52]Van Bezooijen RL, Van Der Wee-Pals L, Papapoulos SE,et al. Interleukin 17 synergises with tumour necrosis factor alpha to induce cartilage destruction in vitro[J]. Ann Rheum Dis,2002;61(10):870-6
[53]Lubberts E, Koenders MI, van den Berg WB. The role of T-cell interleukin-17 in conducting destructive arthritis:lessons from animal models[J]. Arthritis Res Ther,2005;7(1):29-37
[54]Torikai E, Kageyama Y, Takahashi M,et al. The effect of methotrexate on bone metabolism markers in patients with rheumatoid arthritis[J]. Mod Rheumatol,2006;16(6):350-4
[55]Korczowska I, Lacki JK, Hrycaj P. Influence of infliximab on cytokines network and markers of bone remodeling in rheumatoid arthritis patients[J]. Yonsei Med J, 2013;54(1):183-8
[56]Bettelli E, Carrier Y, Gao W,et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells[J]. Nature,2006;441(7090):235-8
[57]Mangan PR, Harrington LE, O'Quinn DB,et al. Transforming growth factor-beta induces development of the T(H)17 lineage[J]. Nature,2006;441 (7090):231-4
[58]Dessein PH. Joffe BL, Singh S. Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis[J]. Arthritis Res Ther,2005; 7 (3) R634-43
[1]Sellar GC, Blake DJ, Reid KB. Characterization and organization of the genes encoding the A-, B-and C-chains of human complement subcomponent Clq. The complete derived amino acid sequence of human Clq[J]. Biochem J,1991;274 (Pt 2):481-90
[2]Kishore U, Reid KB. Clq:structure, function, and receptors[J]. Immunopharmacology, 2000;49(l-2):159-70
[3]Kishore U, Gupta SK, Perdikoulis MV,et al. Modular organization of the carboxyl-terminal, globular head region of human Clq A, B, and C chains[J]. J Immunol,2003;171(2):812-20
[4]Kishore U, Ghai R, Greenhough TJ,et al. Structural and functional anatomy of the globular domain of complement protein Clq[J]. Immunol Lett,2004;95 (2):113-28
[5]Kojouharova MS, Gadjeva MG, Tsacheva IG,et al. Mutational analyses of the recombinant globular regions of human Clq A, B, and C chains suggest an essential role for arginine and histidine residues in the Clq-IgG interaction [J]. J Immunol,2004;172(7):4351-8
[6]Gadjeva MG, Rouseva MM, Zlatarova AS,et al. Interaction of human Clq with IgG and IgM:revisited[J]. Biochemistry,2008;47(49):13093-102
[7]Zlatarova AS, Rouseva M, Roumenina LT,et al. Existence of different but overlapping IgG-and IgM-binding sites on the globular domain of human Clq[J]. Biochemistry,2006;45(33): 9979-88
[8]Nauta AJ, Trouw LA, Daha MR,et al. Direct binding of Clq to apoptotic cells and cell blebs induces complement activation [J]. Eur J Immunol,2002; 32(6):1726-36
[9]Roos A, Xu W, Castellano G,et al. A pivotal role for innate immunity in the clearance of apoptotic cells[J]. Eur J Immunol,2004;34(4):921-9
[10]Navratil JS, Watkins SC, Wisnieski JJ,et al. The globular heads of Clq specifically recognize surface blebs of apoptotic vascular endothelial cells[J]. J Immunol,2001; 166(5): 3231-9
[11]Zwart B, Ciurana C, Rensink I,et al. Complement activation by apoptotic cells occurs predominantly via IgM and is limited to late apoptotic (secondary necrotic) cells[J]. Autoimmunity,2004;37(2):95-102
[12]Sjoberg AP, Manderson GA, Morgelin M,et al. Short leucine-rich glycoproteins of the extracellular matrix display diverse patterns of complement interaction and activation[J]. Mol Immunol,2009;46(5):830-9
[13]Danesh J, Wheeler JG, Hirschfield GM,et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease[J]. N Engl J Med,2004; 350(14):1387-97
[14]Erlinger TP, Platz EA, Rifai N,et al. C-reactive protein and the risk of incident colorectal cancer[J]. JAMA,2004;291(5):585-90
[15]Biro A, Rovo Z, Papp D,et al. Studies on the interactions between C-reactive protein and complement proteins[J]. Immunology,2007;121(1):40-50
[16]McGrath FD, Brouwer MC, Arlaud GJ,et al. Evidence that complement protein Clq interacts with C-reactive protein through its globular head region[J]. J Immunol,2006; 176(5):2950-7
[17]Biro A, Thielens NM, Cervenak L,et al. Modified low density lipoproteins differentially bind and activate the C1 complex of complement[J]. Mol Immunol,2007;44(6):1169-77
[18]Biro A, Ling WL, Arlaud GJ. Complement protein Clq recognizes enzymatically modified low-density lipoprotein through unesterified fatty acids generated by cholesterol esterase[J]. Biochemistry,2010;49(10):2167-76
[19]Kawai Y, Saito A, Shibata N,et al. Covalent binding of oxidized cholesteryl esters to protein:implications for oxidative modification of low density lipoprotein and atherosclerosis[J]. J Biol Chem,2003;278(23):21040-9
[20]Yin W, Ghebrehiwet B, Weksler B,et al. Classical pathway complement activation on human endothelial cells[J]. Mol Immunol,2007;44(9):2228-34
[21]Peerschke El, Yin W, Grigg SE,et al. Blood platelets activate the classical pathway of human complement[J]. J Thromb Haemost,2006;4(9):2035-42
[22]Peerschke El, Yin W, Alpert DR,et al. Serum complement activation on heterologous platelets is associated with arterial thrombosis in patients with systemic lupus erythematosus and antiphospholipid antibodies[J]. Lupus,2009; 18(6):530-8
[23]Roumenina LT, Popov KT, Bureeva SV,et al. Interaction of the globular domain of human Clq with Salmonella typhimurium lipopolysaccharide[J]. Biochim Biophys Acta,2008;1784(9):1271-6
[24]Bonaparte RS, Hair PS, Banthia D,et al. Human astrovirus coat protein inhibits serum complement activation via C1, the first component of the classical pathway[J]. J Virol,2008; 82(2):817-27
[25]Hair PS, Gronemus JQ, Crawford KB,et al. Human astrovirus coat protein binds Clq and MBL and inhibits the classical and lectin pathways of complement activation[J]. Mol Immunol,2010;47(4):792-8
[26]Oberkersch R, Attorresi AI, Calabrese GC. Low-molecular-weight heparin inhibition in classical complement activation pathway during pregnancy [J]. Thromb Res,2010; 125(5): e240-5
[27]Nayak A, Ferluga J, Tsolaki AG,et al. The non-classical functions of the classical complement pathway recognition subcomponent Clq[J]. Immunol Lett,2010;131(2): 139-50
[28]Farber K, Cheung G, Mitchell D,et al. Clq, the recognition subcomponent of the classical pathway of complement, drives microglial activation[J]. J Neurosci Res,2009;87(3): 644-52
[29]Fraser DA, Pisalyaput K, Tenner AJ. Clq enhances microglial clearance of apoptotic neurons and neuronal blebs, and modulates subsequent inflammatory cytokine production [J]. J Neurochem,2010;112(3):733-43
[30]Bonifati DM, Kishore U. Role of complement in neurodegeneration and neuroinflammation[J]. Mol Immunol,2007;44(5):999-1010
[31]Stevens B, Allen NJ, Vazquez LE,et al. The classical complement cascade mediates CNS synapse elimination[J]. Cell,2007;131(6):1164-78
[32]Csomor E, Bajtay Z, Sandor N,et al. Complement protein C1q induces maturation of human dendritic cells[J]. Mol Immunol,2007;44(13):3389-97
[33]Castellano G, Woltman AM, Schlagwein N,et al. Immune modulation of human dendritic cells by complement[J]. Eur J Immunol,2007;37(10):2803-11
[34]van Montfoort N, de Jong JM, Schuurhuis DH,et al. A novel role of complement factor C1q in augmenting the presentation of antigen captured in immune complexes to CD8+T lymphocytes[J]. J Immunol,2007;178 (12):7581-6
[35]Yurasov S, Wardemann H, Hammersen J,et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus[J]. J Exp Med,2005;201 (5):703-11
[36]Groeneveld TW, Oroszlan M, Owens RT,et al. Interactions of the extracellular matrix proteoglycans decorin and biglycan with Clq and collectins[J], J Immunol,2005;175(7): 4715-23
[37]Fraser DA, Laust AK, Nelson EL,et al. C1q differentially modulates phagocytosis and cytokine responses during ingestion of apoptotic cells by human monocytes, macrophages, and dendritic cells[J]. J Immunol,2009;183 (10):6175-85
[38]Ogden CA, deCathelineau A, Hoffmann PR,et al. C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinoc-ytosis and uptake of apoptotic cells[J]. J Exp Med,2001;194(6):781-95
[39]Ghebrehiwet B, Lim BL, Peerschke EI,et al. Isolation, cDNA cloning, and overexpression of a 33-kD cell surface glycoprotein that binds to the globular "heads" of C1q[J]. J Exp Med,1994;179(6):1809-21
[40]Ghebrehiwet B, Peerschke El. cC1q-R (calreticulin) and gC1q-R/p33:ubiquitously expressed multi-ligand binding cellular proteins involved in inflammation and infection[J]. Mol Immunol,2004;41(2-3):173-83
[41]Peterson KL, Zhang W, Lu PD,et al. The Clq-binding cell membrane proteins cC1q-R and gC1q-R are released from activated cells:subcellular distribution and immunochemical characterization[J]. Clin Immunol Immunopathol,1997; 84(1):17-26
[42]Dedio J, Jahnen-Dechent W, Bachmann M,et al. The multiligand-binding protein gC1qR, putative C1q receptor, is a mitochondrial protein[J]. J Immunol,1998;160(7):3534-42
[43]Lim BL, Reid KB, Ghebrehiwet B,et al. The binding protein for globular heads of complement C1q, gC1qR. Functional expression and characterization as a novel vitronectin binding factor[J]. J Biol Chem,1996;271(43):26739-44
[44]Fausther-Bovendo H, Vieillard V, Sagan S,et al. HIV gp41 engages gC1qR on CD4+T cells to induce the expression of an NK ligand through the PIP3/H2O2 pathway[J]. PLoS Pathog,2010;6:e1000975
[45]Peerschke El, Ghebrehiwet B. The contribution of gC1qR/p33 in infection and inflammation[J]. Immunobiology,2007;212(4-5):333-42
[46]Gardai SJ, Xiao YQ, Dickinson M,et al. By binding SIRPalpha or calreticulin/CD91, lung collectins act as dual function surveillance molecules to suppress or enhance inflammation[J]. Cell,2003;115(1):13-23
[47]Michalak M, Corbett EF, Mesaeli N,et al. Calreticulin:one protein, one gene, many functions[J]. Biochem J,1999;344(Pt 2):281-92
[48]Gregory CD, Devitt A. The macrophage and the apoptotic cell:an innate immune interaction viewed simplistically[J]. Immunology,2004;113(1):1-14
[49]Vegh Z, Kew RR, Gruber BL,et al. Chemotaxis of human monocyte-derived dendritic cells to complement component Clq is mediated by the receptors gC1qR and cC1qR[J]. Mol Immunol,2006;43(9):1402-7
[50]Fonseca MI, Carpenter PM, Park M,et al. C1qR(P), a myeloid cell receptor in blood, is predominantly expressed on endothelial cells in human tissue[J]. J Leukoc Biol,2001;70(5): 793-800
[51]Nepomuceno RR, Ruiz S, Park M,et al. C1qRP is a heavily O-glycosylated cell surface protein involved in the regulation of phagocytic activity[J]. J Immunol,1999;162(6): 3583-9
[52]McGreal E, Gasque P. Structure-function studies of the receptors for complement Clq[J]. Biochem Soc Trans,2002;30(Pt 6):1010-4
[53]Eggleton P, Tenner AJ, Reid KB. C1q receptors[J]. Clin Exp Immunol,2000;120(3):406-12
[54]Duus K, Hansen EW, Tacnet P,et al. Direct interaction between CD91 and Clq[J]. FEBS J, 2010;277(17):3526-37
[55]Trouw LA, Blom AM, Gasque P. Role of complement and complement regulators in the removal of apoptotic cells[J]. Mol Immunol,2008;45(5):1199-207
[56]Sjoberg AP, Trouw LA, Blom AM. Complement activation and inhibition:a delicate balance[J]. Trends Immunol,2009;30(2):83-90
[57]Hietala MA, Nandakumar KS, Persson L,et al. Complement activation by both classical and alternative pathways is critical for the effector phase of arthritis[J]. Eur J Immunol, 2004;34(4):1208-16
[58]Shingu M, Watanabe Y, Tomooka K,et al. Complement degradation products in rheumatoid arthritis synovial fluid[J]. Br J Rheumatol,1994;33(3):299-300
[59]Neumann E, Barnum SR, Tamer IH,et al. Local production of complement proteins in rheumatoid arthritis synovium[J]. Arthritis Rheum,2002;46(4):934-45
[60]Wouters D, Voskuyl AE, Molenaar ET,et al. Evaluation of classical complement pathway activation in rheumatoid arthritis:measurement of Clq-C4 complexes as novel activation products[J]. Arthritis Rheum,2006;54(4):1143-50
[61]Konttinen YT, Ceponis A, Meri S,et al. Complement in acute and chronic arthritides: assessment of C3c, C9, and protectin (CD59) in synovial membrane[J]. Ann Rheum Dis, 1996;55(12):888-94
[62]Kurreeman FA, Padyukov L, Marques RB,et al. A candidate gene approach identifies the TRAF1/C5 region as a risk factor for rheumatoid arthritis[J]. PLoS Med,2007;4(9):e278
[63]Molenaar ET, Voskuyl AE, Familian A,et al. Complement activation in patients with rheumatoid arthritis mediated in part by C-reactive protein[J]. Arthritis Rheum,2001;44(5): 997-1002
[64]Merlini G, Bellotti V. Molecular mechanisms of amyloidosis[J]. N Engl J Med, 2003;349(6):583-96
[65]Westermark P, Benson MD, Buxbaum JN,et al. Amyloid fibril protein nomenclature[J]. Amyloid,2002;9(3):197-200
[66]Tuglular S, Yalcinkaya F, Paydas S,et al. A retrospective analysis for aetiology and clinical findings of 287 secondary amyloidosis cases in Turkey[J]. Nephrol Dial Transplant, 2002;17(11):2003-5
[67]Hazenberg BP, van Gameren Ⅱ, Bijzet J,et al. Diagnostic and therapeutic approach of systemic amyloidosis[J]. Neth J Med,2004;62(4):121-8
[68]Tanaka F, Migita K, Honda S,et al. Clinical outcome and survival of secondary (AA) amyloidosis[J]. Clin Exp Rheumatol,2003;21(3):343-6
[69]Joss N, McLaughlin K, Simpson K,et al. Presentation, survival and prognostic markers in AAamyloidosis[J]. QJM,2000;93(8):535-42
[70]Gillmore JD, Lovat LB, Persey MR,et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein[J]. Lancet, 2001;358(9275):24-9
[71]Bellotti V, Chiti F. Amyloidogenesis in its biological environment:challenging a fundamental issue in protein misfolding diseases[J]. Curr Opin Struct Biol,2008;18(6): 771-9
[72]Merlini G, Seldin DC, Gertz MA. Amyloidosis:pathogenesis and new therapeutic options[J]. J Clin Oncol,2011;29(14):1924-33
[73]Uversky VN. Mysterious oligomerization of the amyloidogenic proteins[J]. FEBS J, 2010;277(14):2940-53
[74]Sakono M, Zako T. Amyloid oligomers:formation and toxicity of Abeta oligomers[J]. FEBS J,2010;277(6):1348-58
[75]Stix B, Kahne T, Sletten K,et al. Proteolysis of AA amyloid fibril proteins by matrix metalloproteinases-1,-2, and-3[J]. Am J Pathol,2001;159(2):561-70
[76]van der Hilst JC, Yamada T, Op den Camp HJ,et al. Increased susceptibility of serum amyloid A 1.1 to degradation by MMP-1:potential explanation for higher risk of type AA amyloidosis[J]. Rheumatology (Oxford),2008;47(11):1651-4
[77]Elimova E, Kisilevsky R, Szarek WA,et al. Amyloidogenesis recapitulated in cell culture:a peptide inhibitor provides direct evidence for the role of heparan sulfate and suggests a new treatment strategy[J]. FASEB J,2004;18(14):1749-51
[78]Li JP, Galvis ML, Gong F,et al. In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis [J]. Proc Natl Acad Sci USA,2005;102(18):6473-7
[79]Ma B, Nussinov R. Selective molecular recognition in amyloid growth and transmission and cross-species barriers[J]. J Mol Biol,2012;421(2-3):172-84
[80]Larsson A, Malmstrom S, Westermark P. Signs of cross-seeding:aortic medin amyloid as a trigger for protein AA deposition[J]. Amyloid,2011;18(4):229-34
[81]Westermark GT, Westermark P. Serum amyloid A and protein AA:molecular mechanisms of a transmissible amyloidosis[J]. FEBS Lett,2009;583(16):2685-90
[82]Jucker M, Walker LC. Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders[J]. Ann Neurol,2011;70(4):532-40
[83]Sponarova J, Nystrom SN, Westermark GT. AA-amyloidosis can be transferred by peripheral blood monocytes[J]. PLoS One,2008;3(10):e3308
[84]Nakamura T, Higashi S, Tomoda K,et al. Significance of SAA1.3 allele genotype in Japanese patients with amyloidosis secondary to rheumatoid arthritis[J]. Rheumatology (Oxford),2006;45(1):43-9
[85]Lachmann HJ, Goodman HJ, Gilbertson JA,et al. Natural history and outcome in systemic AAamyloidosis[J]. N Engl J Med,2007;356(23):2361-71
[86]Nakamura T, Yamamura Y, Tomoda K,et al. Efficacy of cyclophosphamide combined with prednisolone in patients with AA amyloidosis secondary to rheumatoid arthritis[J]. Clin Rheumatol,2003;22(6):371-5
[87]Nakamura T. Clinical strategies for amyloid A amyloidosis secondary to rheumatoid arthritis[J]. Mod Rheumatol,2008;18(2):109-18
[88]Nakayamada S, Saito K, Nakatsuka K,et al. A case of rheumatoid arthritis with secondary amyloidosis in urinary bladder[J]. Ryumachi,2002;42(3):618-23
[89]Nakamura T, Yamamura Y, Tomoda K,et al. Massive hematuria due to bladder amyloidosis in patients with rheumatoid arthritis:three case reports[J]. Clin Exp Rheumatol,2003;21(5): 673-4
[90]Tanaka F, Migita K, Honda S,et al. Clinical outcome and survival of secondary (AA) amyloidosis[J]. Clin Exp Rheumatol,2003;21(3):343-6
[91]Rader DJ. Inflammatory markers of coronary risk[J]. N Engl J Med,2000; 343(16): 1179-82
[92]Bokarewa M, Abrahamson M, Levshin N,et al. Cystatin C binds serum amyloid A, downregulating its cytokine-generating properties[J]. J Rheumatol,2007;34 (6):1293-301
[93]Kurth I, Horsten U, Pflanz S,et al. Importance of the membrane-proximal extracellular domains for activation of the signal transducer glycoprotein 130[J]. J Immunol,2000; 164 (1):273-82
[94]Dillon SR, Sprecher C, Hammond A,et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice[J]. Nat Immunol,2004;5(7):752-60
[95]Pflanz S, Hibbert L, Mattson J,et al. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27[J]. J Immunol,2004;172(4):2225-31
[96]Emery P, Keystone E, Tony HP,et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals:results from a 24-week multicentre randomised placebo-controlled trial[J]. Ann Rheum Dis,2008;67(11):1516-23
[97]Heinrich PC, Behrmann I, Haan S,et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation [J]. Biochem J,2003;374(Pt 1):1-20
[98]Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease[J]. Cytokine Growth Factor Rev,2002;13(4-5):357-68
[99]Kishimoto T. IL-6:from its discovery to clinical applications[J]. Int Immunol,2010;22(5): 347-52
[100]Tanaka T, Kishimoto T. Targeting interleukin-6:all the way to treat autoimmune and inflammatory diseases[J]. Int J Biol Sci,2012;8(9):1227-36
[101]Hein GE, Kohler M, Oelzner P,et al. The advanced glycation end product pentosidine correlates to IL-6 and other relevant inflammatory markers in rheumatoid arthritis[J]. Rheumatol Int,2005;26(2):137-41
[102]Rooney T, Roux-Lombard P, Veale DJ,et al. Synovial tissue and serum biomarkers of disease activity, therapeutic response and radiographic progression:analysis of a proof-of-concept randomised clinical trial of cytokine blockade[J]. Ann Rheum Dis,2010;69 (4):706-14
[103]Choy E. Inhibiting interleukin-6 in rheumatoid arthritis[J]. Curr Rheumatol Rep,2008; 10(5):413-7